Point of Care Infectious Disease Testing Market Size & Growth Forecast 2027–2036, By Segments (Technology, Disease, End Use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Point of Care Infectious Disease Testing Market size was around USD 14 billion in 2026 and is slated to grow at a 2.57% CAGR from 2027 to 2036, crossing USD 18.04 billion by 2036. The industry revenue for 2027 is calculated at USD 14.3 billion.
Get more details on this report
Request Free Sample ReportPoint of Care Infectious Disease Testing Market Intelligence Snapshot
Regional Market Dynamics
- North America held a 53.55% market share in 2026, supported by established rapid testing infrastructure and widespread use of decentralized diagnostics across multiple healthcare settings.
- Asia Pacific is projected to expand at a 5.02% CAGR as decentralized healthcare access improves and demand rises for rapid testing that enables faster diagnosis and treatment decisions.
Segment Momentum
- Molecular diagnostics leads with a 45.58% share due to high sensitivity and accuracy, enabling rapid and reliable clinical decisions directly at the point of care.
- Pneumonia and streptococcus-associated infections are growing fastest as demand rises for rapid respiratory differentiation to enable quicker treatment decisions in decentralized care settings.
Market Expansion Drivers
- Rising infectious disease burden driving rapid demand for decentralized diagnostic solutions.
- Growing home healthcare adoption enabling decentralized and patient-centric testing models.
- Government-backed screening programs expanding access to rapid point-of-care diagnostics.
Leading Market Participants
- Prominent players in the point of care infectious disease testing market include Abbott Laboratories (United States), F. Hoffmann-La Roche Ltd (Switzerland), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (United States), Becton, Dickinson and Company (United States), bioMérieux SA (France), Bio-Rad Laboratories, Inc. (United States), Quest Diagnostics Incorporated (United States), Trinity Biotech plc (Ireland), QuidelOrtho Corporation (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 14 billion
- 2027 Estimated Market Size: USD 14.3 billion.
- Projected Market Size: USD 18.04 billion by 2036
- Growth Forecast: 2.57% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Molecular Diagnostics (Technology) | COVID-19 (Disease) | Hospitals (End Use)
- Emerging Opportunity Segment: Lateral Flow Immunoassay (Technology) | Pneumonia or Streptococcus Associated Infections (Disease) | Home (End Use)
Market Growth Drivers and Industry Trends
Rising infectious disease burden driving rapid demand for decentralized diagnostic solutions
The growing prevalence of infectious diseases will drive the point of care infectious disease testing market growth by increasing the need for rapid diagnostic solutions that can be deployed outside centralized laboratory settings. Decentralized testing enables healthcare providers to identify infections closer to the patient and obtain results within shorter clinical workflows, supporting timely treatment decisions and reducing dependence on laboratory transportation and processing. This capability is particularly valuable during outbreaks and in settings where conventional laboratory infrastructure is limited, as portable diagnostic platforms can facilitate testing in clinics, emergency care facilities, community health centers, and other locations where immediate disease identification is required.
Growing home healthcare adoption enabling decentralized and patient-centric testing models
Expansion of home healthcare services will propel the point of care infectious disease testing market as healthcare delivery increasingly shifts toward convenient, patient-centered diagnostic models. Home-based testing allows individuals to access infectious disease screening without making frequent visits to hospitals or diagnostic laboratories, supporting earlier identification and monitoring of infections. The availability of easy-to-use testing devices can also improve accessibility for elderly individuals, patients with mobility limitations, and populations located far from healthcare facilities. Integration of rapid diagnostics into home healthcare workflows further supports remote consultations by providing healthcare professionals with timely test results for clinical assessment and treatment decisions.
Government-backed screening programs expanding access to rapid point-of-care diagnostics
Government-supported infectious disease screening initiatives will boost the point of care infectious disease testing market demand by expanding the deployment of rapid diagnostic technologies across public healthcare systems and community-based programs. Screening campaigns can require testing solutions that are portable, easy to administer, and capable of delivering timely results in diverse environments, including underserved communities and high-risk populations. Wider implementation of such programs also encourages healthcare facilities to strengthen decentralized testing capacity, particularly where centralized laboratory access is constrained. Rapid point-of-care diagnostics can support broader screening coverage while helping healthcare workers identify suspected infections and initiate appropriate clinical pathways more efficiently.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising infectious disease burden driving rapid demand for decentralized diagnostic solutions | 1.80% | High | North America, Asia Pacific | High | Near Term |
| Growing home healthcare adoption enabling decentralized and patient-centric testing models | 1.50% | Moderate | North America, Europe | High | Mid Term |
| Government-backed screening programs expanding access to rapid point-of-care diagnostics | 1.30% | High | Asia Pacific, Africa | Medium | Long Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America accounted for the largest share of the point of care infectious disease testing market at 53.55% in 2026, supported by advanced healthcare infrastructure, strong diagnostic capabilities, and broad adoption of rapid testing technologies across clinical settings. Demand is reinforced by the need for timely diagnosis and treatment decisions, growing emphasis on decentralized healthcare delivery, and established reimbursement and regulatory frameworks that facilitate the use of point-of-care diagnostics.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is advancing as the fastest-growing regional market, driven by expanding healthcare access, increasing infectious disease surveillance needs, and investments in diagnostic infrastructure. The growing use of rapid testing in hospitals, clinics, community settings, and underserved areas is improving access to timely diagnosis, while rising healthcare awareness and technological improvements are supporting broader adoption of portable and easy-to-use diagnostic solutions.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Clinical Workflow EfficiencyGermany prioritizes point-of-care infectious disease testing that delivers reliable diagnostic results with minimal turnaround time. Healthcare facilities continue integrating decentralized testing solutions to strengthen infection management and routine clinical services.
France 🇫🇷
Decentralized Care SupportFrance continues expanding point-of-care infectious disease testing across outpatient clinics and community healthcare environments. Diagnostic providers emphasize ease of use, reliable performance, and faster treatment decisions closer to the point of care.
Italy 🇮🇹
Accessible Diagnostic ServicesItaly is increasing the use of point-of-care infectious disease testing to improve access to timely diagnosis in hospitals and local healthcare facilities. Healthcare organizations prioritize portable diagnostic systems that simplify testing while maintaining clinical reliability.
Japan 🇯🇵
Compact Testing InnovationJapan supports compact and highly accurate point-of-care infectious disease testing for hospitals, primary care, and elderly healthcare services. Diagnostic developers focus on user-friendly systems with rapid performance and dependable analytical quality.
South Korea 🇰🇷
Digital Diagnostic IntegrationSouth Korea is integrating point-of-care infectious disease testing with digital healthcare platforms and connected laboratory systems. Healthcare providers value rapid diagnostics that enhance patient triage and support efficient disease surveillance.
United States 🇺🇸
Rapid Diagnostic AdoptionThe U.S. emphasizes rapid point-of-care infectious disease testing to support timely clinical decisions across hospitals, clinics, and community healthcare settings. Healthcare providers increasingly adopt multiplex diagnostic platforms that improve workflow efficiency and patient management.
Segment Leadership and Growth Trends
Point of Care Infectious Disease Testing Market Share (%), by Technology, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportTechnology Segment Analysis: Molecular Diagnostics (Largest Segment) vs Lateral Flow Immunoassay (Fastest-Growing Segment)
Molecular diagnostics represented a 45.58% share of the point of care infectious disease testing market in 2026, supported by the ability of molecular techniques to provide highly specific identification of infectious pathogens. Their application is particularly valuable where timely and reliable diagnostic information can support clinical decision-making and appropriate treatment management. Increasing emphasis on rapid diagnosis and decentralized healthcare is encouraging the use of advanced molecular testing closer to patients. Continued demand for accurate pathogen detection is therefore sustaining the segment's leading position.
Lateral flow immunoassay is the fastest-growing technology segment, supported by its simplicity, portability, and suitability for decentralized testing environments. These assays can provide convenient testing without requiring the extensive infrastructure associated with more complex diagnostic technologies, making them relevant across diverse point-of-care settings. Growing demand for accessible and rapid infectious disease screening is expanding opportunities for lateral flow-based testing. Their operational simplicity and suitability for near-patient use are strengthening adoption across healthcare environments.
Disease Segment Analysis: COVID-19 (Largest Segment) vs Pneumonia or Streptococcus Associated Infections (Fastest-Growing Segment)
The COVID-19 segment accounted for a 64.99% share in 2026 within the point of care infectious disease testing market, reflecting the substantial importance of rapid testing capabilities for respiratory infectious disease management. The need for accessible detection and timely clinical assessment established point-of-care testing as an important component of infectious disease response. Continued awareness of respiratory infection surveillance and the value of decentralized diagnostic access are supporting the segment's established position. Demand for convenient testing remains relevant where rapid identification can assist healthcare providers in making informed care decisions.
Pneumonia or streptococcus associated infections are the fastest-growing disease segment, driven by continued demand for timely identification of infections that can require prompt clinical intervention. Point-of-care testing can support faster diagnostic assessment in settings where immediate laboratory access may be limited or where rapid treatment decisions are important. Increasing preference for decentralized diagnostic approaches is creating additional opportunities for testing related to respiratory and bacterial infections. The broader focus on early detection and accessible infectious disease management is supporting growth within this segment.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Technology | Lateral Flow Immunoassay, Agglutination Test, Flow-through test/Immunoconcentration Assay, Molecular Diagnostics, Others | Molecular Diagnostics | Lateral Flow Immunoassay |
| Disease | HIV POC, Clostridium Difficile POC, HBV POC, Pneumonia or Streptococcus Associated Infections, Respiratory Syncytial Virus (RSV) POC, HPV POC, Influenza/Flu POC, HCV POC, MRSA POC, TB & Drug-resistant TB POC, HSV POC, COVID-19, Others | COVID-19 | Pneumonia or Streptococcus Associated Infections |
| End Use | Clinics, Hospitals, Home, Assisted Living Healthcare Facilities, Laboratory | Hospitals | Home |
Competitive Landscape and Market Positioning
Leading companies in the point of care infectious disease testing market:
1. Abbott Laboratories (United States)
2. F. Hoffmann-La Roche Ltd (Switzerland)
3. Siemens Healthineers AG (Germany)
4. Thermo Fisher Scientific Inc. (United States)
5. Becton Dickinson and Company (United States)
6. bioMérieux SA (France)
7. Bio-Rad Laboratories Inc. (United States)
8. Quest Diagnostics Incorporated (United States)
9. Trinity Biotech plc (Ireland)
10. QuidelOrtho Corporation (United States)
Rising need for rapid diagnostics is driving expansion in the point of care infectious disease testing market, particularly in decentralized healthcare settings. Innovations in portable testing formats are improving turnaround time and accessibility. Continuous advancement in diagnostic sensitivity is enhancing reliability across use cases. The point of care infectious disease testing market is increasingly shaped by the demand for faster, more accessible healthcare solutions.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories (United States) | |||||||
| F. Hoffmann-La Roche Ltd (Switzerland) | |||||||
| Siemens Healthineers AG (Germany) | |||||||
| Thermo Fisher Scientific Inc. (United States) | |||||||
| Becton Dickinson and Company (United States) | |||||||
| bioMérieux SA (France) | |||||||
| Bio-Rad Laboratories Inc. (United States) | |||||||
| Quest Diagnostics Incorporated (United States) | |||||||
| Trinity Biotech plc (Ireland) | |||||||
| QuidelOrtho Corporation (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Biomerieux | Mar-24 | Biomerieux received U.S. FDA 510(k) clearance and CLIA waiver for its BIOFIRE SPOTFIRE Respiratory/Sore Throat Panel, strengthening its position in rapid infectious disease diagnostics. The approval enables broader clinical adoption and enhances competitive positioning in point-of-care respiratory testing. |
| Roche | Jan-24 | Roche acquired LumiraDx’s point-of-care diagnostic technology, strengthening its POC portfolio with a portable multi-disease testing platform covering infectious diseases, cardiovascular conditions, diabetes, and coagulation disorders. The acquisition enhances Roche’s capabilities in decentralized diagnostics and broadens its rapid testing product ecosystem. |
| Thermo Fisher | Feb-23 | Thermo Fisher partnered with Mylab to launch made-in-India RT-PCR kits for infectious disease testing, aiming to expand access to diagnostic testing across India and other markets. The collaboration strengthens localized manufacturing and distribution of molecular diagnostic solutions. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Point of Care Infectious Disease Testing Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Sample Type | Blood & Serum/Plasma, Nasal & Nasopharyngeal Samples, Saliva & Oral Fluid, Urine, Stool & Other Specimens |
| Purchase Channel | Direct Manufacturer Sales, Medical Device Distributors, Group Purchasing Organizations, Retail & Pharmacy Channels |
| Testing Model | Single-Patient Rapid Testing, Batch & Sequential Testing, Multiplex Testing, Integrated Test Panels |
Point of Care Infectious Disease Testing Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Decentralized Diagnostics Adoption Strategy |
|
| Multiplex Testing Technology Opportunity Study |
|
| Infectious Disease Testing Access Expansion Analysis |
|
Need a different cut of the data?
Request Custom ResearchWhat is the market valuation of point of care infectious disease testing?
How is the point of care infectious disease testing industry size expected to evolve during the forecast period?
How is decentralization of diagnostics reshaping demand in the point of care infectious disease testing market?
How are home healthcare and government screening programs expanding adoption of point-of-care infectious disease testing?
What drives molecular diagnostics to lead the point-of-care infectious disease testing market?
Which disease segment is showing the fastest growth in point-of-care infectious disease testing?
What factors make North America the leading point of care infectious disease testing market?
What is fueling growth in the Asia Pacific point of care infectious disease testing market?
Which companies dominate the point of care infectious disease testing landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization